Archived explainer. For the current picture see today's EWTX page.
EDGEWISE THERAPEUTIC (EWTX) is down -8.48% in the latest session. Our newswire has captured 5 stories on EWTX across 3 sources in the last 36 hours, with AI sentiment reading bullish (avg 60/100).
EWTX stock is down 8.48% at $41.56 as of the latest trade, reflecting a sharp sell-off following the announcement of the sale of its muscular dystrophy assets to Servier. The company’s strategic shift toward its cardiovascular pipeline appears to have triggered a reassessment by investors, who are factoring in the implications of the deal. The move comes amid mixed sentiment from recent coverage, with AI sentiment averaging 60 out of 100, slightly above neutral.
Edgewise Therapeutics announced the completion of the sale of its sevasemten compound and muscular dystrophy assets to Servier for up to $2.65 billion, according to a PR Newswire report. The transaction includes an upfront payment of $1.55 billion and potential milestone payments of up to $1.1 billion. The company described the move as a strategic step to focus its resources on its cardiovascular pipeline. A separate SEC 8-K filing confirmed the disposition of assets, with details including financial and regulatory disclosures. TipRanks also reported the sale, noting the transaction’s impact on the company’s asset portfolio. Additional PR Newswire reports from both English and French sources highlighted Servier’s strategic interest in rare neurological diseases, reinforcing the deal’s significance.
The intraday session saw a sharp decline after an early high of $48.51. The stock fell to a session low of $43.81 by midday and closed the session at $45.40, with a volume of 0.7 million shares, or 0.5 times the 3-month daily average. The stock is currently trading within its 52-week range of $12.30 to $43.93. EWTX remains unprofitable with a trailing twelve-month EPS of -1.66 and a market cap of $4.3 billion. The stock’s beta of 0.28 indicates relatively low volatility compared to the broader market.
While no earnings date is provided, investors should monitor the evolving coverage landscape. Recent analyst ratings from Oppenheimer, Guggenheim, and RBC Capital remain optimistic, with price targets above the current price. The market will likely assess how the strategic refocus on cardiovascular assets aligns with long-term growth expectations.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Not financial advice.
Edgewise Therapeutics ( ($EWTX) ) just unveiled an announcement. On July 10, 2026, Edgewise Therapeutics completed the sale of its sevasemten compound and muscular ...
Filed: 2026-07-13 AccNo: 0001104659-26-082902 Size: 226 KB Item 2.01: Completion of Acquisition or Disposition of Assets Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
— Edgewise receives $1.55 billion in upfront cash and is eligible to receive up to $1.1 billion in regulatory and commercial milestones — — Transaction creates strategically focused cardiovascular company — — Upfront proceeds expected to fully fund EDG-7500 development through potential...
Cette acquisition soutient l'ambition stratégique de Servier dans les maladies neurologiques rares avec le sevasemten, un traitement expérimental à un stade avancé de développement pour les dystrophies musculaires de Becker et de Duchenne. L'actif acquis et l'équipe d'experts renforcent...
Acquisition supports Servier's strategic ambition in rare neurology with sevasemten, a late-stage investigational treatment for Becker and Duchenne muscular dystrophies. The acquired asset and expert team strengthen Servier's commitment to innovate for patients with high unmet medical...
More on EWTX: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier EWTX move explainers: 2026-07-17 · 2026-07-14 · 2026-07-13